Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Pouplin, Thomas ^a,b   Bang, Nguyen Duc ^c,d   Toi, Pham Van ^c   Phuong, Pham Nguyen ^c   Dung, Nguyen Huy ^d   Duong, Tran Ngoc ^d   Caws, Maxine ^b,c,e   Thwaites, Guy E ^b,c   Tarning, Joel ^a,b   Day, Jeremy N ^b,c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^d Pham Ngoc Thach Hospital   (Viet Nam)

^e LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Anti tuberculosis drugs; Children; HPLC; Meningitis; Pharmacokinetics; Rifampicin; TB

Indexed keywords

ETHAMBUTOL; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; STREPTOMYCIN; ARYLAMINE ACETYLTRANSFERASE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; AGE; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; ELIMINATION HALF-LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOUS MENINGITIS; VIETNAMESE; VOLUME OF DISTRIBUTION; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CEREBROSPINAL FLUID; GENETICS; GENOTYPE; HALF LIFE TIME; INFANT; TUBERCULOSIS, MENINGEAL; VIET NAM;

ADOLESCENT; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; INFANT; ISONIAZID; MALE; PROSPECTIVE STUDIES; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS, MENINGEAL; VIETNAM;

EID: 84962030134     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1470-x     Document Type: Article

References (53)

1. Farinha NJ, Razali KA, Holzel H, Morgan G, Novelli VM. Tuberculosis of the central nervous system in children: a 20-year survey. J Infect. 2000;41:61-8.
2. Marx GE, Chan ED. Tuberculous meningitis: diagnosis and treatment overview. Tuberc Res Treat. 2011;2011:798764.
3. Peloquin CA, Jaresko GS, Yong C, Keung ACF, Bulpitt AMYE, Jelliffe RW. Population Pharmacokinetic Modeling of Isoniazid, Rifampin, and Pyrazinamide. Antimicrob Agents Chemother. 1997;41:2670-9.
4. Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis. 2010;90:279-92.
5. Gundert-Remy U, Klett M, Weber E. Concentration of ethambutol in cerebrospinal fluid in man as a function of the non-protein-bound drug fraction in serum. Eur J Clin Pharmacol. 1973;6:133-6.
6. Ellard GA, Humphries M, Gabriel M, Teoh R. Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis. Br Med J. 1987;294:284-5.
7. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2012;3099:1-9.
8. Heemskerk D, Day J, Chau TTH, et al. Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial. Trials. 2011;12:1-11.
9. van Toorn R, Schaaf HS, Laubscher J a, van Elsland SL, Donald PR, Schoeman JF. Short intensified treatment in children with drug-susceptible tuberculous meningitis. Pediatr Infect Dis J. 2014;33:248-52.
10. Wolbers M, Heemskerk D, Chau TTH, et al. Sample size requirements for separating out the effects of combination treatments: randomised controlled trials of combination therapy vs. standard treatment compared to factorial designs for patients with tuberculous meningitis. Trials. 2011;12:26.
11. Guidance for national tuberculosis programmes on the management of tuberculosis in children. WHO report 2006. Geneva, World Health Organization, 2006 (WHO/HTM/TB/2006.371 - WHO/FCH/CAH/2006.7).
12. Thwaites GE. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;531:1741-51.
13. Brans R, Laizane D, Khan A, Blömeke B. N-acetyltransferase 2 genotyping: an accurate and feasible approach for simultaneous detection of the most common NAT2 alleles. Clin Chem. 2004;50:1264-6.
14. Rihs H-P, John A, Scherenberg M, Seidel A, Brüning T. Concordance between the deduced acetylation status generated by high-speed: real-time PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay. Clin Chim acta. 2007;376:240-3.
15. Kilbane a J, Silbart LK, Manis M, Beitins IZ, Weber WW. Human N-acetylation genotype determination with urinary caffeine metabolites. Clin Pharmacol Ther. 1990;47:470-7.
16. Notarianni LJ, Dobrocky P, Godlewski G, Jones RW, Bennett PN. Caffeine as a metabolic probe: NAT2 phenotyping. Br J Clin Pharmacol. 1996;41:169-73.
17. Tiwari G, Tiwari R. Bioanalytical method validation: An updated review. Pharm Methods. 2010;1:25-38.
18. Prahl JB, Johansen IS, Cohen AS, Frimodt-Møller N, Andersen AB. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. J Antimicrob Chemother. 2014;69:2841-7.
19. Ruslami R, Nijland HMJ, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2007;51:2546-51.
20. Reynolds J, Heysell SK. Understanding pharmacokinetics to improve tuberculosis treatment outcome. Expert Opin Drug Metab Toxicol. 2014;10:1-11.
21. Mugabo P, Hassan MS, Slaughter R. Acute Pharmacokinetics of First Line Anti-tuberculosis Drugs in Patients with Pulmonary Tuberculosis and in Patients with Pulmonary Tuberculosis Co-infected with HIV. J US-China Med Sci. 2011;8:661-6.
22. Mitchison DA, Davies GR. Assessment of the Efficacy of New Anti-Tuberculosis Drugs. Open Infect Dis J. 2008;2:59-76.
23. Ramachandran G, Kumar AK, Swaminathan S. Pharmacokinetics of anti-tuberculosis drugs in children. Indian J Pediatr. 2011;78:435-42.
24. Ramachandran G, Hemanth Kumar AK, Bhavani PK, et al. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children. Int J Tuberc Lung Dis. 2013;17:800-6.
25. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62:2169-83.
26. Foster BJ, Platt RW, Zemel BS. Development and validation of a predictive equation for lean body mass in children and adolescents. Ann Hum Biol. 2012;39:171-82.
27. Pouplin T, Phuong PN, Van Toi P, Nguyen Pouplin J, Farrar J. Isoniazid, pyrazinamide and rifampicin content variation in split fixed-dose combination tablets. PLoS One. 2014;9:e102047.
28. Donald PR, Maritz JS, Diacon AH. Pyrazinamide pharmacokinetics and efficacy in adults and children. Tuberculosis. 2012;92:1-8.
29. Rey E, Gendrel D, Treluyer JM, et al. Isoniazid pharmacokinetics in children according to acetylator phenotype. Fundam Clin Pharmacol. 2001;15:355-9.
30. Schaaf HS, Parkin DP, Seifart HI, et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child. 2005;90:614-8.
31. Thee S, Seddon JA, Donald PR, et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother. 2011;55:5560-7.
32. Mahmood I. Naive pooled-data approach for pharmacokinetic studies in pediatrics with a very small sample size. Am J Ther. 2014;21:269-74.
33. Graham SM, Sismanidis C, Menzies HJ, Marais BJ, Detjen AK, Black RE. Importance of tuberculosis control to address child survival. Lancet. 2014;6736:5-7.
34. Marais BJ, Graham SM. Childhood tuberculosis: a roadmap towards zero deaths. Journal of Paediatrics and Child Health. 2014. doi:10.1111/jpc.12647.
35. Shingadia D. Tuberculosis in childhood. Ther Adv Respir Dis. 2012;6:161-71.
36. van Well GTJ, Paes BF, Terwee CB, et al. Twenty Years of Pediatric Tuberculous Meningitis: A Retrospective Cohort Study in the Western Cape of South Africa. Pediatrics. 2009;123:e1-8.
37. Donald PR. The chemotherapy of tuberculous meningitis in children and adults. Tuberculosis. 2010;90:375-92.
38. Thee S, Detjen A, Wahn U, Magdorf K. Rifampicin serum levels in childhood tuberculosis. Int J Tuberc Lung Dis. 2009;13:1106-11.
39. Graham SM, Bell DJ, Nyirongo S, et al. Low Levels of Pyrazinamide and Ethambutol in Children with Tuberculosis and Impact of Age, Nutritional Status, and Human Immunodeficiency Virus Infection. Antimicrob Agents Chemother. 2006;50:407-13.
40. McLeay SC, Morrish GA, Kirkpatrick CMJ, Green B. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet. 2012;51:319-30.
41. Holford N. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30:329-32.
42. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis. 2003;7:6-21.
43. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis. 2000;4:796-806.
44. Donald PR, Sirgel FA, Venter A, et al. The Influence of Human N-Acetyltransferase Genotype on the Early Bactericidal Activity of Isoniazid. Clin Infect Dis. 2004;39:1425-30.
45. Donald PR, Sirgel FA, Botha FJ, et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med. 1997;156:895-900.
46. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis. 1980;121:939-49.
47. McIlleron H, Willemse M, Werely CJ, et al. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. Clin Infect Dis. 2009;48:1547-53.
48. Diacon AH, Patientia RF, Venter A, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother. 2007;51:2994-6.
49. Diacon AH, Donald PR. The early bactericidal activity of antituberculosis drugs. Expert Rev Anti Infect Ther. 2014;12:223-37.
50. Steingart KR, Jotblad S, Robsky K, et al. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review [Review article]. Int J Tuberc Lung Dis. 2011;15:305-16.
51. te Brake L, Dian S, Ganiem AR, et al. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Int J Antimicrob Agents. 2015;45(5):496-503.
52. Mariappan TT, Singh S, Pandey R, Khuller GK. Determination of Absolute Bioavailability of Rifampicin by Varying the Mode of Intravenous Administration and the Time of Sampling. Clin Res Regul Aff. 2005;22:119-28.
53. Koup JR, Williams-Warren J, Viswanathan CT, Weber A, Smith AL. Pharmacokinetics of rifampin in children. II. Oral bioavailability. Ther Drug Monit. 1986;8:17-22.